- Home
- LDI vs RIGL Comparison
LDI vs RIGL Comparison
Compare LDI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDI | RIGL |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 683.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LDI | RIGL |
|---|---|---|
| Price | $2.17 | $34.64 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.00 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 4.8M | 431.9K |
| Earning Date | 03-10-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | ★ $1,095,780,000.00 | $282,076,000.00 |
| Revenue This Year | $28.65 | $66.37 |
| Revenue Next Year | $20.19 | N/A |
| P/E Ratio | ★ N/A | $5.63 |
| Revenue Growth | 10.74 | ★ 79.13 |
| 52 Week Low | $1.01 | $15.50 |
| 52 Week High | $5.05 | $52.24 |
Technical Indicators
Market Signals| Indicator | LDI | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 35.10 |
| Support Level | $2.55 | $36.38 |
| Resistance Level | $2.89 | $37.83 |
| Average True Range (ATR) | 0.20 | 1.73 |
| MACD | -0.05 | -0.37 |
| Stochastic Oscillator | 2.23 | 11.98 |
Price Performance
Historical ComparisonAbout LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.